Multiple Sclerosis | Disease Landscape & Forecast | G7 | 2025
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab), and Roche’s subcutaneous Ocrevus Zunovo heighten competition in the dominant anti-CD20 class. Despite clinical setbacks for some emerging BTK inhibitors in relapsing MS, the class holds promise in underserved progressive MS populations, with key readouts for Sanofi’s tolebrutinib and Roche’s fenebrutinib coming in 2025. With oral generics a reality in the United States and Europe, the first biosimilar (i.e., Sandoz’s Tyruko [natalizumab-sztn]) has also launched and others are expected to reach market before 2034. Understanding and navigating these market dynamics will be crucial for the success of both current and future players in this evolving landscape.
Questions answered:
- What is the commercial outlook for emerging oral BTK inhibitors in relapsing and progressive forms of MS given current clinical evidence?
- What commercial impact could Sanofi’s frexalimab have for both relapsing and nonrelapsing SP-MS patients?
- How will Briumvi, Kesimpta, and Ocrevus Zunovo impact the use of Ocrevus in the relapsing and progressive MS markets?
- What do key opinion leaders think about emerging agents for relapsing and progressive MS patients, and what is the commercial outlook for these therapies?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan
Primary research: Country-specific interviews with thought-leading neurologists; survey data collected for this and other Clarivate research
Epidemiology: Diagnosed and drug-treated prevalence of total MS, CIS, RR-MS, SP-MS, and PP-MS
Drug treatments: Coverage of key current and late-phase emerging therapies
Forecast: 10-year, annualized, drug-level sales and patient share of key MS therapies through 2034, segmented by brands / generics and epidemiological subpopulations
Product description
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
